Lee Eugene, Park Chang Min, Kang Keon Wook, Goo Jin Mo, Kim Min A, Paeng Jin Chul, Lee Hyun Ju, Park Heae Surng, Chung Doo Hyun
Department of Radiology, Seoul National University College of Medicine, and Institute of Radiation Medicine, Seoul National University Medical Research Center, Seoul, Korea.
Acta Radiol. 2013 Feb 1;54(1):24-9. doi: 10.1258/ar.2011.110474. Epub 2012 Jan 30.
Pulmonary sclerosing hemangioma (PSH) has been reported to show increased FDG uptake and be potential false-positives on 18F-FDG PET/CT examination. However, it is still unclear whether the previously-reported high FDG uptake is a universal characteristic of PSH, and furthermore, there have been no investigations on what kind of radiologic or histologic features may have been related with its FDG uptake values.
To investigate the 18F-FDG PET/CT features of pulmonary sclerosing hemangiomas (PSHs), and to evaluate the relating factors with their FDG uptake values.
We identified 10 PSHs in eight patients who had a pathologic diagnosis and available antecedent 18F-FDG PET/CT images. 18F-FDG PET/CT images were investigated both qualitatively and quantitatively, along with their histopathologic features. Correlation between 18F-FDG PET features and radiologic as well as histopathologic features were also evaluated.
Mean diameter of the 10 PSHs in our study was 16.9 mm ± 6.26 (range 5-25 mm). Four tumors showed intense uptake, and four tumors showed moderate uptake on 18F-FDG PET/CT scans. In the remaining two tumors, there were no significant FDG uptakes. The SUVmax of tumors ranged from 0.60-4.7 (median 2.30; 2.51 ± 1.42), and was significantly correlated with the tumor size (r = 0.754, P = 0.012) and three out of four tumors ≥2 cm (75%) showed intense FDG uptake and their SUVmax values were greater than 2.5. Immunohistochemical results for GLUT-1, GLUT-4, and Ki-67 and other pathologic features were not correlated with the tumors' FDG uptake.
The majority of PSHs show increased FDG uptakes, and their SUVmax values are significantly correlated with their tumor size. PSH ≥2 cm can frequently be falsely interpreted as malignancy in FDG-PET/CT. Further studies with large study population are warranted to confirm our observations.
据报道,肺硬化性血管瘤(PSH)在18F-FDG PET/CT检查中表现为FDG摄取增加,可能出现假阳性。然而,先前报道的高FDG摄取是否为PSH的普遍特征仍不清楚,此外,尚未有研究探讨哪些放射学或组织学特征可能与其FDG摄取值相关。
探讨肺硬化性血管瘤(PSH)的18F-FDG PET/CT特征,并评估与其FDG摄取值相关的因素。
我们在8例经病理诊断且有可用的18F-FDG PET/CT图像的患者中识别出10个PSH。对18F-FDG PET/CT图像进行了定性和定量研究,并结合其组织病理学特征。还评估了18F-FDG PET特征与放射学及组织病理学特征之间的相关性。
本研究中10个PSH的平均直径为16.9 mm±6.26(范围5-25 mm)。在18F-FDG PET/CT扫描中,4个肿瘤表现为强烈摄取,4个肿瘤表现为中度摄取。其余2个肿瘤无明显FDG摄取。肿瘤的SUVmax范围为0.60-4.7(中位数2.30;2.51±1.42),与肿瘤大小显著相关(r = 0.754,P = 0.012),4个≥2 cm的肿瘤中有3个(75%)表现为强烈FDG摄取,其SUVmax值大于2.5。GLUT-1、GLUT-4和Ki-67的免疫组化结果及其他病理特征与肿瘤的FDG摄取无关。
大多数PSH表现为FDG摄取增加,其SUVmax值与肿瘤大小显著相关。在FDG-PET/CT中,≥2 cm的PSH常被误诊为恶性肿瘤。需要进一步进行大样本研究以证实我们的观察结果。